Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Light chain amyloidosis 2012: a new era.

Gatt ME, Palladini G.

Br J Haematol. 2013 Mar;160(5):582-98. doi: 10.1111/bjh.12191. Epub 2013 Jan 7. Review.

PMID:
23294331
2.

[Current treatment of AL amyloidosis].

Desport E, Moumas E, Abraham J, Delbès S, Lacotte-Thierry L, Touchard G, Fermand JP, Bridoux F, Jaccard A.

Nephrol Ther. 2011 Nov;7(6):467-73. doi: 10.1016/j.nephro.2011.02.003. Epub 2011 Apr 15. Review. French.

PMID:
21497573
3.

Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.

Gertz MA.

Am J Hematol. 2014 Dec;89(12):1132-40. doi: 10.1002/ajh.23828. Review.

4.

Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.

Kristen AV, Rosenberg M, Lindenmaier D, Merkle C, Steen H, Andre F, Schönland SO, Schnabel PA, Schuster T, Röcken C, Giannitsis E, Katus HA, Frey N.

Amyloid. 2014 Sep;21(3):202-10. doi: 10.3109/13506129.2014.940457. Epub 2014 Jul 9.

PMID:
25007036
5.

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.

Bone Marrow Transplant. 2001 Oct;28(7):637-42. Review.

6.

Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.

Mahmood S, Venner CP, Sachchithanantham S, Lane T, Rannigan L, Foard D, Pinney JH, Gibbs SD, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD.

Br J Haematol. 2014 Sep;166(6):842-8. doi: 10.1111/bjh.12973. Epub 2014 Jun 13.

PMID:
24930361
7.

[Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].

Adam Z, Sčudla V, Krejčí M, Cermáková Z, Pour L, Král Z.

Vnitr Lek. 2013 Jan;59(1):37-58. Review. Czech.

PMID:
23428001
8.

Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.

Gertz MA, Dispenzieri A.

Oncology (Williston Park). 2012 Feb;26(2):152-61. Review.

9.

Light-chain amyloidosis: SCT, novel agents and beyond.

Rosenzweig M, Giralt S, Landau H.

Bone Marrow Transplant. 2013 Aug;48(8):1022-7. doi: 10.1038/bmt.2012.199. Epub 2012 Oct 29. Review.

PMID:
23103675
10.

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.

Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA.

Am J Hematol. 2010 Oct;85(10):757-9. doi: 10.1002/ajh.21822.

11.

Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.

Sher T, Hayman SR, Gertz MA.

Clin Adv Hematol Oncol. 2012 Oct;10(10):644-51. Erratum in: Clin Adv Hematol Oncol. 2012 Nov;10(11):766.

PMID:
23187770
12.

[Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].

Adam Z, Pour L, Krejcí M, Zahradová L, Krivanová A, Mardová J, Kovárová L, Stepánková S, Moulis M, Kren L, Veselý K, Svobodová I, Germáková Z, Nedbálková M, Mayer J, Hájek R.

Vnitr Lek. 2010 Mar;56(3):190-209. Review. Czech.

PMID:
20394205
13.

[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].

Charliński G, Wiater E, Jedrzejczak WW.

Pol Merkur Lekarski. 2012 Apr;32(190):217-20. Polish.

PMID:
22708276
14.

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP.

Haematologica. 2014 Sep;99(9):1479-85. doi: 10.3324/haematol.2014.104109. Epub 2014 May 23.

15.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO.

J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.

PMID:
25779559
16.

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA.

J Clin Oncol. 2012 Mar 20;30(9):989-95. doi: 10.1200/JCO.2011.38.5724. Epub 2012 Feb 13.

17.

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.

Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, Dimopoulos MA.

Haematologica. 2007 Oct;92(10):1351-8.

18.

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.

Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L, Nuvolone M, Brugnatelli S, Invernizzi R, Merlini G.

Ann Hematol. 2012 Jan;91(1):89-92. doi: 10.1007/s00277-011-1244-x. Epub 2011 Apr 30.

PMID:
21533608
19.

Managing systemic light-chain amyloidosis.

Comenzo RL.

J Natl Compr Canc Netw. 2007 Feb;5(2):179-87. Review.

PMID:
17335687
20.

Future directions in the clinical management of amyloid light-chain amyloidosis.

Haider S, Ahmad N, Anaissie E, Driscoll JJ.

Leuk Lymphoma. 2014 Oct;55(10):2241-51. doi: 10.3109/10428194.2013.876630. Epub 2014 Feb 24. Review.

PMID:
24359238

Supplemental Content

Support Center